Warning over access to mental health services for
LACK of access to mental health services for people affected by neurological conditions is profoundly impacting the wellbeing of people across Scotland, a report has said.
It was released today by the Neurological Alliance of Scotland, which says the underfunded neurological third sector is struggling to cope with the volume and intensity of demand for mental health support among those affected by neurological conditions who cannot get support from the NHS.
The report highlights significant increases in calls to helplines since 2017, with charities are increasingly having to deal with safeguarding issues as carers reach burnout and there are reports of increasingly complex calls to helplines, including suicidal ideation and complex posttraumatic stress disorder (PTSD).
In addition, the report points out that the NHS routinely refers people to neurological charities for social and emotional support yet does not provide third sector with enough funding to deal with these referrals.
It is noted that a steady year on year increase in the prevalence of neurological conditions, coupled with extended NHS waiting times and difficulty accessing services has led to overwhelming demand on the neurological third sector. The report goes on to highlight how early intervention to support mental health at the earliest stages of diagnosis of a neurological condition, often provided by third-sector specialists, has a huge cost benefit.
It says this is particularly true for children and young people who are being routinely failed by long waiting times to access CAMHS as well as for those affected by complex, degenerative, or fluctuating conditions.
Keith Park, chair of the Neurological Alliance of Scotland Mental Health Subgroup and
of her case was removed from trial data. If substantiated, this is a breach of every principle of GCP and the Declaration of Helsinki.
What has been established clinically is that mRNA technology doesn’t replicate at the site of administration as was originally suggested. It travels to distant tissue and replicates spike protein in all tissue and organs. This is problematic for a variety of reasons.
According to esteemed University of London Professor of Oncology, and principal of the Institute for Cancer
Vaccines and Immunotherapy, Professor Angus Dalgleish, this has precipitated serious and sometimes fatal consequences.
He and other clinical academics have been arguing for some time that the vaccine has induced a coagulation condition called Thrombotic Thrombocytopenia Syndrome (TTS) which leads to both blood clot formation and a reduction in available platelet cells needed for normal blood clot formation.
This can lead to stroke, pulmonary emboli (lung clots) and heart attacks, all of which can be life limiting or fatal. Another antibody that Dalgleish has linked to the spike protein exerts an effect on myelin and is associated with paralysing Guillain-Barre Syndrome (GBS) and Transverse Myelitis, a swelling of the spinal cord.
In a speech in the Commons last month, I cited multiple clinical studies and reviews raising further serious concerns about mRNA vaccines including their impact on cardiac inflammatory markers, cancer relapse, excess mortality, and the abandonment of ethical practice in the rush to find a vaccine during a once in a century pandemic.
I have also uncovered that the Medicines and Healthcare products Regulatory Agency (MHRA) has received 489,004 Covid-19 vaccine suspected adverse drug reaction reports, 2734 of which are associated
with a fatal outcome. The true number is unknown, due to limited public awareness, under-reporting and – most worryingly – a refusal from the Office of National Statistics (ONS) and UK Government to open Record Level Data (RLD) to clinical academic scrutiny.
The need for an urgent rethink has been given fresh impetuous following Astra Zeneca’s admission that “the AZ vaccine can, in very rare cases, cause TTS”. This admission runs counter to previous comments in 2023 that AZ would “not accept that TTS is caused by the vaccine” and comes after a £100 million class action lawsuit was filed in the UK on behalf of 50 victims claiming the vaccine was responsible for severe injuries and deaths.
This is an important development for victims because the government’s own Vaccine Damage Payment Scheme is totally inadequate.
I raised this specific point during the recent debate and I am pleased to see that Health Secretary Victoria Atkins has since ordered a review of the scheme as Covid vaccine claims soar.
The bottom line is that dogma, hyperbole and adherence to false received wisdom won’t cut it. We must investigate the impact of mRNA as a technology without agenda.
As I said at the start of this column, there is nothing to be gained by trying to protect any individual, organisation, corporate or political interest for risk is to be understood, managed and mitigated.
Questions being raised on this issue must be answered with full access to ONS record level data for clinical academics as a minimum. If we are to tackle the problem, we must first understand the extent of it.
None of these clinical experts are quacks or conspiracy theorists.
As the Government said so often during the pandemic, we must follow the science.